New York, Jan 7, 2026, 14:12 EST — Regular session
- Thermo Fisher shares down about 0.2% in afternoon trade after a three-day run.
- TD Cowen lifted its price target to $696 from $654, keeping a “buy” rating.
- Investors are looking to a Jan. 13 conference presentation and the Jan. 29 results for fresh demand signals.
Thermo Fisher Scientific shares edged lower on Wednesday after TD Cowen raised its price target on the life-sciences tools maker, with investors taking stock after the stock’s sprint to a fresh 52-week high.
The pullback matters because Thermo Fisher is coming into a busy stretch of scheduled events. Chief Executive Marc Casper is due to present at the J.P. Morgan Healthcare Conference on Jan. 13, and quarterly results follow on Jan. 29 — two chances for management to frame demand from pharma and biotech customers after a strong start to the year for U.S. equities.
At about 2:12 p.m. EST, Thermo Fisher was down roughly 0.25% at $619.19. The stock finished Tuesday up 1.56% at $620.72, hitting a new 52-week high in that session on above-average volume.
TD Cowen analyst Dan Brennan lifted his 12-month price target to $696 from $654 and maintained a “buy” rating on Jan. 7, according to Benzinga data. Benzinga
Broader markets were mixed, with technology shares extending their rally while investors digested labor-market data. “If you get weaker economic news … you’re like should I have been chasing the market or should I take some profit,” Robert Pavlik, senior portfolio manager at Dakota Wealth, said. Reuters
A Form 4 filing showed director Karen S. Lynch received 53.93 phantom stock units under the company’s deferred compensation plan for directors, tied to the closing price at quarter-end, dated Dec. 31 and filed on Jan. 5. Form 4s are disclosures insiders file to report changes in holdings.
Still, the stock’s run leaves little room for disappointment if Thermo Fisher’s outlook fails to reassure on order trends, margins or customer spending. Any sign of slower demand for lab tools and services could hit expectations quickly with shares near recent highs.
Next up is Casper’s Jan. 13 presentation at the J.P. Morgan Healthcare Conference, followed by the Jan. 29 earnings release and conference call before the U.S. market opens.
